Rein Therapeutics, Inc. (RNTX)
0.791
-0.01
(-1.12%)
USD |
NASDAQ |
Sep 21, 16:00
0.791
0.00 (0.00%)
After-Hours: 20:00
Rein Therapeutics Enterprise Value : 72.97M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 72.97M |
| September 17, 2026 | 72.05M |
| September 16, 2026 | 64.58M |
| September 15, 2026 | 65.04M |
| September 14, 2026 | 72.20M |
| September 11, 2026 | 71.69M |
| September 10, 2026 | 71.33M |
| September 09, 2026 | 75.33M |
| September 08, 2026 | 78.33M |
| September 04, 2026 | 80.61M |
| September 03, 2026 | 76.71M |
| September 02, 2026 | 70.81M |
| September 01, 2026 | 68.91M |
| August 31, 2026 | 68.67M |
| August 28, 2026 | 69.72M |
| August 27, 2026 | 71.50M |
| August 26, 2026 | 72.97M |
| August 25, 2026 | 72.97M |
| August 24, 2026 | 72.97M |
| August 21, 2026 | 74.52M |
| August 20, 2026 | 72.42M |
| August 19, 2026 | 72.29M |
| August 18, 2026 | 70.41M |
| August 17, 2026 | 76.51M |
| August 14, 2026 | 73.49M |
| Date | Value |
|---|---|
| August 13, 2026 | 71.90M |
| August 12, 2026 | 73.40M |
| August 11, 2026 | 74.42M |
| August 10, 2026 | 72.46M |
| August 07, 2026 | 74.47M |
| August 06, 2026 | 71.99M |
| August 05, 2026 | 65.63M |
| August 04, 2026 | 69.86M |
| August 03, 2026 | 68.30M |
| July 31, 2026 | 67.60M |
| July 30, 2026 | 70.23M |
| July 29, 2026 | 69.37M |
| July 28, 2026 | 71.41M |
| July 27, 2026 | 71.39M |
| July 24, 2026 | 72.23M |
| July 23, 2026 | 72.98M |
| July 22, 2026 | 76.40M |
| July 21, 2026 | 81.10M |
| July 20, 2026 | 76.75M |
| July 17, 2026 | 78.30M |
| July 16, 2026 | 78.29M |
| July 15, 2026 | 85.51M |
| July 14, 2026 | 82.90M |
| July 13, 2026 | 82.19M |
| July 10, 2026 | 88.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 1.980B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.375M |
| Total Expenses (Quarterly) | 6.375M |
| EPS Diluted (Quarterly) | -0.095 |
| Earnings Yield | -217.2% |
| Normalized Earnings Yield | -120.37 |